Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.

Séverine VermeireBruce E SandsLaurent Peyrin-BirouletGeert R D'HaensJulian PanésAndres J YarurDouglas C WolfTimothy RitterStefan SchreiberJohn C WoolcottIrene ModestoMichael KeatingKevin ShanJoseph WuMichael V ChioreanFilip BaertMarla C DubinskyMartina GoetschSilvio DaneseBrian G Feagan

Published in: Journal of Crohn's & colitis (2024)

Bio/JAKi-naïve and -experienced patients had clinically meaningful induction and maintenance treatment benefits with etrasimod vs placebo.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
rheumatoid arthritis
peritoneal dialysis
randomized controlled trial
bone marrow
double blind
cell therapy
phase iii
open label
replacement therapy